SGLT2 Inhibitors, GLP-1 RAs Not Cost-Effective as First-Line T2D Agents
(MedPage Today) -- Although using newer classes of diabetes drugs as first-line therapy can boost life expectancy, this strategy can be quite pricey, according to a cost-effectiveness study.
Compared with traditional first-line metformin, first...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Fortamet | Heart | Metformin | SGLT2 Inhibitors | Study